FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 345:1214-1215 October 18, 2001 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: A 63-year-old man with a dense left hemiplegia from a stroke two and a half years earlier was seen in the clinic in May 2000 with clinical evidence of relapsed malignant melanoma of the scalp. Stage II malignant melanoma over the vertex had first been diagnosed in March 1999. In July 1999, the lesion was widely excised, with a 1-cm margin of normal tissue. The diameter of the melanoma was 1 cm and its depth 4 mm. The margin was tumor-free. He received no adjuvant therapy. In March 2000, two lesions developed, one measuring 10 by 8 . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Markovic, S. N., Erickson, L. A., Rao, R. D., Weenig, R. H., Pockaj, B. A., Bardia, A., Vachon, C. M., Schild, S. E., McWilliams, R. R., Hand, J. L., Laman, S. D., Kottschade, L. A., Maples, W. J., Pittelkow, M. R., Pulido, J. S., Cameron, J. D., Creagan, E. T., Melanoma Study Group of the Mayo Clinic Cancer Cen, (2007). Malignant Melanoma in the 21st Century, Part 2: Staging, Prognosis, and Treatment. Mayo Clin Proc. 82: 490-513 [Abstract] [Full Text]  
• Danson, S., Lorigan, P., Arance, A., Clamp, A., Ranson, M., Hodgetts, J., Lomax, L., Ashcroft, L., Thatcher, N., Middleton, M.R. (2003). Randomized Phase II Study of Temozolomide Given Every 8 Hours or Daily With Either Interferon Alfa-2b or Thalidomide in Metastatic Malignant Melanoma. JCO 21: 2551-2557 [Abstract] [Full Text]